Company Dossier · Health Care
Waters Corporation
- S&P 500
- Russell 1000
What Waters Corporation is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to July 4, 2026: $4.64 billion, up 52% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.01 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $0.07 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 4, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 5 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 23, 2026): 12 risk factors added, 4 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $1.4 million on the open market.SEC Form 4
- 1,186 institutional managers reported a position at June 30, 2026 (+8 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 15 (12 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Waters Corporation is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding · Confident
Expanding ↔ Retrenching
Expanding
- Capital spending—
- Debt raised83rd pct
- Buybacks vs capex—
- Hiring filings95th pct
- Deals and private raises88th pct
- Patent publications81st pct
Confident ↔ Hedging
Confident
- Call sentiment88th pct
- Call confidence85th pct
- Guidance changes62nd pct
- Risk factors added6th pct
- Insider open-market trades39th pct
- + Call sentiment
- + Call confidence
- − Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver60th pct
- Stress filings48th pct
Credit
How these are built →Waters Corporation's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$5.1B
- Due within a year $0.2B
- Longer term $4.9B
- Default point $2.6B (short + ½ long)
Finance leases included · Jul 4, 2026 filing
Bonds priced, last 12 months
$3.5B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Mar 17, 2026 | $650M | 4.321% | 2027 (2y) | +65bp | 4.321% |
| Mar 17, 2026 | $600M | 4.398% | 2029 (3y) | +72bp | 4.398% |
| Mar 17, 2026 | $750M | 4.656% | 2031 (5y) | +87bp | 4.656% |
| Mar 17, 2026 | $750M | 4.945% | 2033 (7y) | +97bp | 4.945% |
| Mar 17, 2026 | $750M | 5.245% | 2036 (10y) | +105bp | 5.245% |
From the pricing term sheets Waters Corporation filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (ERNST & YOUNG LLP (WASHINGTON COUNCIL ERNST & YOUNG))third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 13, 2026Patent
- Oct 6, 2026Patent
- Sep 29, 2026Patent
- Sep 29, 2026Patent
- Sep 23, 2026LobbyingLobbying report (ERNST & YOUNG LLP (WASHINGTON COUNCIL ERNST & YOUNG))third_quarter 2026
- Aug 21, 20268-KDirector or officer changeItem 5.02
- May 22, 20268-KShareholder vote resultsItem 5.07
- Mar 23, 20268-KMaterial agreement signedItem 1.01
- Feb 23, 202610-KAnnual report (10-K)12 risk factors added, 4 removed
- Feb 9, 20268-KMaterial agreement signedItem 1.01
- Feb 9, 20268-KAcquisition or sale completedItem 2.01
- Feb 9, 20268-KDirector or officer changeItem 5.02
- Jan 27, 20268-KShareholder vote resultsItem 5.07
- Jul 14, 20258-KMaterial agreement signedItem 1.01
- May 29, 20258-KMaterial agreement signedItem 1.01
- May 23, 20258-KShareholder vote resultsItem 5.07
- Feb 25, 202510-KAnnual report (10-K)2 risk factors added, 0 removed
- Nov 1, 20248-KDirector or officer changeItem 5.02
- Feb 27, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Illumina, Inc. ILMN | $4.5B | $0.9B | Jun 28, 2026 |
| Mettler Toledo MTD | $4.1B | $0.9B | Jun 30, 2026 |
| Charles River Laboratories CRL | $4.0B | $0.4B | Jun 27, 2026 |
| Agilent Technologies A | $7.4B | $1.3B | Jul 31, 2026 |
| Bio-Rad Laboratories BIO | $2.6B | $0.3B | Jun 30, 2026 |
| IQVIA IQV | $16.6B | $2.1B | Mar 31, 2026 |
| Bio-Techne TECH | $1.2B | $0.3B | Jun 30, 2026 |
| Jazz Pharmaceuticals JAZZ | $4.6B | $1.6B | Jun 30, 2026 |